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ABSTRACT 23 
A resazurin chromogenic agar ( RCA)  along with combined disc method has been 24 
developed as a promising method for rapid screening of extended-spectrum-β-lactamase 25 
( ESBL) , AmpC β-lactamase, and co-production of ESBL and AmpC.  Cefpodoxime 26 
(CPD) discs supplemented with and without clavulanic acid (CA), cloxacillin (CX), or 27 
CA+ CX were evaluated against 86-molecularly confirmed β-lactamase-producing 28 
Enterobacteriaceae, including 15 ESBLs, 32 AmpCs, 9 co-producers of ESBL and 29 
AmpC, and 30 carbapenemase producers.  The CA and CX synergy test successfully 30 
detected all ESBL producers (100%  sensitivity and 98.6%  specificity)  and all AmpC 31 
producers (100%  sensitivity and 96.36%  specificity). This assay also exhibited a good 32 
performance in the screening for the co-existence of ESBL and AmpC ( 88. 89% 33 
sensitivity and 100%  specificity). The RCA assay is a simple and inexpensive method 34 
that allows observation of results within 7 h. It can be applicable in any microbiological 35 
laboratory, especially in the endemic areas of ESBL, AmpC, or co-β-lactamase-36 
producing Enterobacteriaceae. 37 
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1. INTRODUCTION 45 
An increasing number of antibiotic-resistant opportunistic pathogens have been 46 
documented globally in recent years, resulting in decreasing effective antibiotic 47 
availability.  Not surprisingly, these problems have created a treatment challenge and 48 
pose a serious health risk affecting both hospitalized patients and health care providers 49 
(1-3). β-Lactamase-associated resistance is a predominant mechanism of resistance to β-50 
lactam antibiotics in Enterobacteriaceae.  The dissemination of resistance in these 51 
bacteria is frequently facilitated by transferring mobile genetic elements among bacteria 52 
(4). Currently, infections caused by multidrug-resistant (MDR) Gram-negative bacteria, 53 
in particular extended-spectrum-β-lactamases ( ESBL) - producing Enterobacteriaceae, 54 
are among one of the most serious human health concerns ( 5) .  blaTEM, blaSHV, and 55 
blaCTX-M  genes are the most common ESBL genotypes among Enterobacteriaceae. 56 
ESBL-producing isolates characteristically hydrolyze cefotaxime, ceftazidime, cefepime 57 
and/or  monobactam aztreonam, rendering these antibiotics inactive (6-8) .  ESBLs are 58 
inhibited by β-lactamase inhibitors, namely clavulanate, sulbactam and tazobactam. 59 
False-negative ESBL test results using combination disc tests may result from high-60 
level expression of AmpC β-lactamases, which masks the presence of ESBLs. The use 61 
of clavulanic acid (CA) and cloxacillin (CX) together allows detection of co-production 62 
of ESBL and AmpC (9). In addition, AmpC producers and co-producers of AmpC and 63 
ESBL have also been reported to be resistant to third-generation cephalosporins, 64 
cephamycins or β-lactam/β-lactamase inhibitor combinations (10). Infections caused by 65 
AmpC- producing organisms are typically associated with resistance to multiple 66 
antibiotics, including penicillins, oxyimino- 7-α-methoxycephalosporins and 67 
monobactams ( 11, 12) .  In general, AmpC type enzymes are poorly inhibited by β-68 
lactamase inhibitors, especially CA. Phenotypic AmpC confirmation tests are generally 69 
based on inhibition of AmpC by either CX or boronic acid (BA)  derivatives.  BA also 70 
inhibits class A carbapenemases ( 13) , justifying the use of CX in the present study. 71 
Moreover, co-expression of ESBL and AmpC β-lactamases results in decreased 72 
susceptibility to aztreonam and β-lactam/  β-lactamase inhibitors than those with either 73 
ESBL or AmpC β-lactamase alone ( 14) .  This makes the selection of an effective 74 
antibiotic difficult for the treatment of infections caused by these recalcitrant bacteria. 75 
         76 
 A simple, rapid and inexpensive method for screening and discrimination between 77 
these enzymes at a phenotypic level could guide clinicians to prescribe an appropriate 78 
chemotherapy.  The combined disc method has been used extensively because it is 79 
relatively easy to prepare and perform.  However, this test requires at least 18 h or 80 
overnight to obtain the results.  A resazurin reduction assay, a colorimetric method, is 81 
based upon the ability of active cells to reduce the blue colored resazurin to the pink 82 
colored resorufin (15). A colorimetric (resazurin containing) disc susceptibility method 83 
exhibited excellent reproducibility (16)  and high sensitivity and specificity in detection 84 
and differentiation of carbapenemase-producing Enterobacteriaceae (17). Cefpodoxime 85 
( CPD)  is an attractive indicator cephalosporin for detection of ESBL production and 86 
may be used for screening according to EUCAST guidelines.  There are several 87 
diagnostic methods that have been proposed for phenotypic confirmation of ESBL and 88 
AmpC β-lactamases, including the Etest, combined disc method e.g. MAST D68C test, 89 
double disc synergy test, and automated broth microdilution test. These methods usually 90 
take at least 18 h to obtain results (9, 18, 19) . Hence, the present study investigated a 91 
resazurin chromogenic agar ( RCA)  method together with CPD discs alone or  92 
supplemented with CA, CX, and both CA and CX to screen for and discriminate 93 
between ESBL, AmpC, and co-existence of ESBL and AmpC among 94 
Enterobacteriaceae.   95 
2. MATERIALS AND METHODS 96 
2.1  Bacterial isolates  97 
The present study employed a total of 86 β-lactamase-producing Enterobacteriaceae 98 
isolates to evaluate the performance of the RCA assay in rapid screening and 99 
discrimination of ESBL, AmpC, and co-producers of ESBL and AmpC. The organisms 100 
used in the present study are summarized in Table 1 ( 17, 20) .   The molecular types 101 
included 15 Ambler class A ESBL producers (3 CTX-M-3, 1 CTX-M-15,  1 SHV-27, 1 102 
SHV-18, 1 SHV,  1 TEM-214, 1 TEM-10, 1 TEM-70, 1 CTX-M-15+SHV-27, 1 SHV-103 
27+TEM-53,  1 SHV-27+TEM-71 , 1 SHV-110+TEM-84, and 1 CTX-M+SHV+TEM), 104 
32 Ambler class C AmpC producers (6 DHA family, 7 CIT family, 2 MOX family, 11 105 
EBC family, and 6 FOX family)  and 9 co-producers of ESBL and AmpC ( 1 106 
TEM+ ACT-type, 4 CTX-M+ ACT-types, 1 TEM+ SHV+ ACT-type, 1 TEM+ CTX-107 
M+ ACT-type, 1 SHV+ ACT type, and 1 SHV+ CTX-M-ACT-type) .  Thirty 108 
carbapenemase-producing isolates (8 Klebsiella pneumoniae carbapenemase (KPC), 11 109 
metallo-β-lactamase (MBL), and 11 OXA-48 producers) were also included to validate 110 
the performance of the RCA plate assay.   A reference strain E.  coli ATCC 25922 was 111 
used as a negative β-lactamase control strain.  The following β-lactamase-producing 112 
isolates obtained from the American Type Culture Collection ( ATCC)  and National 113 
Collection of Type Cultures ( NCTC)  were used as controls; E.  cloacae ATCC BAA-114 
1143 (blaACT-32), E. coli NCTC 13352 (blaTEM-10) and E. coli NCTC 13353 (blaCTX-M-15). 115 
 116 
2.2 Resazurin chromogenic agar (RCA) plate and disc preparations 117 
RCA plates were prepared according to previous studies ( 16, 17) .  Briefly, 10 mL of 118 
sterile 2.5 mg/mL resazurin sodium salt (Sigma, UK)  was added to 990 mL of sterile 119 
Mueller- Hinton (MH) agar 45-50 °C (Oxoid, UK), then mixed gently and poured into 120 
Petri dishes into Petri dishes to achieve an  approximately 4 mm depth.   121 
 For the preparation of the antibiotic- or β-lactamase inhibitor-containing discs, 10 µg of 122 
CPD discs (MAST Group, UK) were supplemented with 10 µl of 1 mg/mL CA (Sigma-123 
Aldrich, UK) , 10 µl of CX ( Sigma-Aldrich, UK)  at a concentration of 50 mg/mL, or 124 
impregnated with both CA and CX. Meropenem (MER) discs (10 µg) were prepared by 125 
adding 10 µl of MER ( Sigma-Aldrich, UK)  at a concentration of 1 mg/ mL to blank 126 
discs ( 6. 5 mm diameter, MAST Group, UK) .  Prior to performing disc diffusion 127 
susceptibility testing, the discs were air-dried in a biosafety cabinet for 1 h.  128 
2.3 Disc diffusion susceptibility testing 129 
The algorithm for phenotypic screening of ESBL, AmpC, and co-producers of ESBL 130 
and AmpC is illustrated in Figure 1.   The experimental procedure for disc diffusion 131 
susceptibility testing was carried out according to the Clinical Laboratory Standards 132 
Institute ( CLSI)  guidelines ( 21) .  Briefly, a sterile swab soaked in a 0. 5 McFarland 133 
standard of test organism was spread entirely on the surface of the RCA plate.   Discs 134 
containing CPD alone, CPD plus CA, CPD plus CX, CPD plus CA and CX, and MER 135 
alone were placed equidistantly on the RCA’ s surface.  The MER disc was used to 136 
screen for carbapenem resistance including carbapenemase production.  The inhibition 137 
zone diameters were scrupulously measured and interpreted following incubation at 37 138 
°C for 7 h by observing a change in the medium from the original blue ( resazurin) 139 
colour  to pink (resorufin).  The interpretation criteria in screening and differentiation of 140 
ESBL, AmpC, and co-β-lactamases were based upon a previous report as presented in 141 
Table 2 ( 19) .  An increase in zone diameter ( ≥ 5 mm)  of CPD supplemented with β-142 
lactamase inhibitor compared with CPD alone was considered as synergistic activity. To 143 
interpret the results, CA synergy was considered as a positive result for ESBL, while 144 
CX synergy and CA plus CX synergy were noted as positive results for AmpC and co-145 
production of ESBL and AmpC, respectively.  A zone diameter of MER < 25 mm was 146 
used at a cut-off point to screen for the presence of carbapenemases.  Sensitivity and 147 
specificity of the RCA assay with a combined disc method were calculated by 148 
comparing the results with molecular types from PCR and sequencing data. A box-and-149 
whisker plot was analyzed using SPSS statistical analysis program version 18 ( SPSS 150 
Inc, USA)  to elucidate the distribution of zone diameters of discs against different β-151 
lactamase producers.   152 
3.  RESULTS 153 
The use of the RCA assay along with a combined disc method for phenotypic 154 
confirmation of ESBL, AmpC, and co-expression of ESBL plus AmpC clearly showed 155 
the inhibition zone diameters within 7 h (Figure 2).  Figure 3 illustrates the distribution 156 
of the zone diameters of CPD impregnated with and without CA, CX, or CA plus CX, 157 
and MER alone against ESBL, AmpC, co-existence of ESBL and AmpC, and 158 
carbapenemase-producing Enterobacteriaceae.  For screening of ESBL-producing 159 
isolates, the median zone diameter of CPD alone was 6.5 mm (range = 6.5-16 mm) and 160 
the median diameters of CPD supplemented with CA, CX, or CA plus CX were 22 mm 161 
(range = 19-25 mm), 6.5 mm (range = 6.5-17 mm), and 23 mm (range = 21-25 mm), 162 
respectively.   MER discs exhibited potential activity in inhibition of ESBL producers 163 
with a median zone diameter 25 mm (range =  23-27 mm)  (Figure 3A) . A substantial 164 
increase in the zone diameters of CA-containing discs compared with those of discs 165 
without CA was only observed in ESBL-producing isolates.  The mean zone increase of 166 
CPD plus CA compared with CPD alone was 14. 6 mm ( range =  5-17. 5 mm) .  No 167 
marked increase in zone diameter was observed in AmpC producers (mean = 0.48 mm 168 
and range =  1.5-3.5 mm) , co-producers of ESBL and AmpC ( mean =  2.72 mm and 169 
range 1.5-8.5 mm), as well as carbapenemase-producing isolates (mean = 0.37 mm and 170 
range = 0-5.5 mm).  The RCA assay with combined disc method successfully detected 171 
all test ESBL producers with 100% sensitivity and 98.6 % specificity (Table 2). A false-172 
positive result was observed in an OXA-48-producing E. coli.           173 
In AmpC producers, an increase in median zone diameters was seen in CX-containing 174 
discs. CPD plus CX and CPD plus CX plus CA had equally a median zone diameter of 175 
20 mm and a range of 12-26 mm.  The median zone diameter of CPD against these 176 
isolates was 7.25 mm (range = 6.5-20 mm) which was similar to CPD plus CA (median 177 
= 8 mm and range =6.25-21 mm). MER discs inhibited the growth of AmpC-producing 178 
isolates at a median zone diameter of 25 mm and range 23-28mm ( Figure 3B) .   The 179 
mean difference of zone diameter of CPD plus CX versus CPD alone was 10. 1 mm 180 
(range = 5.5 -16.5 mm) against AmpC producers, whilst no dramatic difference in mean 181 
zone increase was observed in ESBL producers (mean =0.33 mm and range = 0-2 mm), 182 
co-producers of ESBL and AmpC ( mean =  4. 33 mm and range =  1-7. 5 mm) , or 183 
carbapenemase producers (mean =  0.88 mm and range =  0-9.5 mm) . The RCA assay 184 
demonstrated an excellence performance in the screening of AmpC-producing strains by 185 
detecting all test AmpC producers ( 100 %  sensitivity) , but there were two false-186 
positives in KPC-3-producing K. pnuemoniae and OXA-48-producing E. coli (96.36 % 187 
specificity; Table 2).               188 
For screening of ESBL and AmpC-co-producing Enterobacteriaceae, CPD discs alone 189 
exhibited a median zone diameter of 9 mm (range = 6.5-22 mm). CPD plus CA (median 190 
= 15 mm and range = 6.5-22 mm) and CPD plus CX (median = 14 mm and range = 10-191 
27 mm)  showed a slight increase in median zone diameter compared with CPD alone. 192 
CPD plus CA plus CX demonstrated excellent activity in inhibiting the growth of ESBL 193 
and AmpC co-producers.  The median zone was significantly increased ( median =  24 194 
mm and range = 21-27 mm) in comparison with those of CPD alone, CPD plus CA, and 195 
CPD plus CX. The median zone diameter and zone range of MER against these isolates 196 
were 25 mm and 23-26 mm, respectively ( Figure 3C) .  The mean difference in zone 197 
diameter of CPD plus CA and CX versus CPD plus CA, or versus CPD plus CX was 198 
also calculated. The mean zone increase of CPD plus CA and CX versus CPD plus CA 199 
was 11. 61 mm (range=5-19.5 mm). A similar result was observed in CPD plus CA and 200 
CX versus CPD plus CX.  The sensitivity and specificity of the RCA assay with the 201 
combined disc method were 88.89% and 100%, respectively (Table 2). The assay failed 202 
to detect ESBL activity in a SHV plus ACT-producing E.  aerogenes.  Furthermore, in 203 
carbapenemase-producing isolates, the median zone diameters of CPD with and without 204 
CA, CX, or CA and CX were not markedly different, while the ranges did vary.  The 205 
MER disc alone had a median zone diameter of 17 mm and range 6. 5-25 mm.  A 206 
reference strain E.  coli ATCC 25922 was inhibited by a CPD disc alone with zone 207 
diameter 25 mm which was in the susceptible range according to the CLSI breakpoint 208 
(≥21 mm) (22). The findings of this study demonstrated that the RCA assay with CPD 209 
combination discs showed an excellent performance in screening of and differentiation 210 
between ESBL, AmpC, and co-production of ESBL and AmpC in Enterobacteriaceae.  211 
 212 
4. DISCUSSION 213 
The present study proposes a rapid screening method using the RCA assay along with 214 
CPD combined disc method to detect the presence of and discriminate between β-215 
lactamases within 7 h.  The CA synergy test using the RCA assay with CPD combined 216 
discs to confirm the presence of ESBL production in Enterobacteriaceae detected all 217 
tested ESBL-producing isolates.  Only one false-positive was found, which was in an 218 
OXA-48-producing isolate.  This finding agrees with a previous report published by 219 
Derbyshire and colleagues (26). They found that a CA synergy test using CPD was able 220 
to detect all 117 ESBL producers indicated by a ≥  5 mm increase in zone diameter of 221 
CPD plus CA in comparison with CPD alone. This synergy test could not detect ESBLs 222 
in the co-presence of AmpCs.  Similarly, CPD exhibited excellent performance in the 223 
screening of ESBL in K.  pneumoniae and E.  coli, but poor sensitivity for K.  oxytoca 224 
( 24, 25) .   The presence of ESBLs may also be masked by carbapenemases such as 225 
MBLs or KPCs ( 26) .  Furthermore, not all OXA-48-variants exhibit significant 226 
carbapenemase activity, some OXA-48 variants such as OXA-163 and OXA-405 have 227 
been reported to be resistant to either carbapenem antibiotics or to extended-spectrum 228 
cephalosporins.  These two variants were significantly inhibited by CA ( 27, 28) .  We 229 
speculate that the OXA-48-producing isolate used in the present study might have low 230 
carbapenemase activity as indicated by relatively large zone diameter for MER (22 mm) 231 
and might also co-produce ESBL.                                                                         232 
For screening of AmpC-producing isolates using CX synergy test, the assay was able to 233 
detect all AmpC producers and two-false positive results (100% Sensitivity and 96.36% 234 
specificity) .  This result is consistent with many previous papers reporting a good 235 
performance of CPD and CX synergy tests in detection of these enzymes (18, 19, 29). In 236 
one such study MAST® D68C successfully detected almost all AmpC producers whilst 237 
a few false-positive results were also reported ( 96. 7 %  sensitivity and 96. 9% 238 
specificity) .  The test could not detect the low production of AmpC β-lactamases in 239 
AmpC-producing isolates (19).  A similar result was reported by Ingram and colleagues, 240 
they found that MAST® D68C exhibited a sensitivity and specificity above 90%  in 241 
detection of the presence of AmpC β-lactamase in Enterobacteriaceae ( 18) .  In 242 
agreement with a previous study, MAST-4 disc demonstrated good sensitivity ( 92% ) 243 
and specificity ( 86. 7% )  in the detection of AmpC-producing nosocomial Klebsiella 244 
isolates ( 29) .  Combined activity of ESBL and AmpC in the same strain can result in 245 
phenotypic detection failure ( 30) .   Co-production with AmpC β-lactamases can mask 246 
ESBL production with CLSI confirmatory tests leading to false-negative results ( 31) . 247 
Therefore, adding two or more specific β-lactamase inhibitors could exclude different 248 
types of β-lactamase in the same strain.  In the present study, we used CA plus CX 249 
synergy test to discriminate co-producers of ESBL and AmpC.   The assay was able to 250 
detect 8 co-producers of ESBL and AmpC.  Only AmpC was detected in one co-251 
producer of ESBL and AmpC.  This false-negative isolate was susceptible to CPD 252 
according to the CLSI breakpoint ( 22) .  The finding from this study is similar to the 253 
result from a previously mentioned study where MAST® D68C was reported to 254 
successfully detect all 8 ESBL and AmpC-co-producing isolates (18).       255 
 To screen carbapenemase-producing isolates, it has been recommended to use a cut-off 256 
point lower than 25 mm for MER disc because the zone diameter of MER in some 257 
OXA-48 like-producing bacteria is still in the susceptible range (≥ 23 mm) (32, 33). The 258 
current study found that MER zone diameters against ESBL, AmpC, and Co-ESBL and 259 
AmpC ranged from 23-28 mm, whilst in carbapenemase-producing isolates zone 260 
diameters ranged from 6.5 – 25 mm.  Only one OXA-48 producing isolate had a zone 261 
diameter of 25 mm. Thus, the isolates showing zone diameters < 25mm for 10 μg MER 262 
disc should be further investigated to detect the distinct type of carbapenemase (MBLs, 263 
KPCs, and OXA-48 like carbapenemases)  or AmpC plus porin loss.  Carbapenem 264 
antibiotics are frequently used for the treatment of the infections caused by AmpC- and 265 
ESBL-producing Gram-negative pathogens ( 34) .  However, overuse of carbapenems 266 
results in development of carbapenem resistance ( 13,35) .  Colistin, fosfomycin, and 267 
tigecycline are among the most frequently used antibiotics for treating these cases (36). 268 
Inclusion of the MER disc allows detection of meopenem resistance, so it is therefore 269 
important in guiding clinicians to appropriate antibiotic treatments. 270 
 To summarize, the combined disc test is commonly used in many microbiological 271 
laboratories, because it is very simple.  The conventional method takes at least 18 h to 272 
observe the inhibition zone diameter.  In the present study, we support the use of the 273 
RCA assay to improve the time to result for the disc diffusion susceptibility test.   The 274 
result from RCA assay can be observed within 7 h.   It also demonstrates excellent 275 
sensitivity and specificity for differentiation of ESBL, AmpC, and co-ESBL and AmpC-276 
producing Enterobacteriaceae.  The RCA assay could be applicable to commercially 277 
available discs, including MAST discs (Mast Group, UK) and it can also be applied in 278 
CLSI ESBL confirmatory tests and any disc diffusion method.  However, a larger 279 
sample size of clinical isolates is still required to further validate and establish the 280 
robustness of this assay. A rapid phenotypic method that can detect and differentiate the 281 
different types of β-lactamase would improve the effectiveness of antibiotic 282 
administration and would also help to control the dissemination of the infection caused 283 
by these refractory bacteria.   284 
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FIGURE LEGENDS  430 
Figure 1.  The algorithm for confirmation of and differentiation between  ESBL, 431 
AmpC, and co-production of ESBL and AmpC in Enterobacteriaceae.   CA= clavulanic 432 
acid (10 µg); CX = cloxacillin (500 µg). 433 
Figure  2.  Phenotypic results from the RCA plate assay with a combined disc method 434 
at 7 h.  A = cefpodoxime (10 µg); B = cefpodoxime (10 µg) + clavulanic acid (10 µg); 435 
C =cefpodoxime (10 µg) + cloxacillin (500 µg); D= cefpodoxime (10 µg) + clavulanic 436 
acid (10 µg) + cloxacillin (500 µg);E = meropenem (10 µg).  437 
Figure 3.  Distribution of zone diameters of cefpodoxime (CPD) alone,   CPD with 438 
clavulanic acid, CPD with cloxacillin, CPD with both clavulanic acid and cloxacillin 439 
and meropenem alone.   A = ESBL producers (n=15); B = AmpC producers (n=32); C= 440 
co-producers AmpC and ESBL (n=9); D = carbapenemase producers (n=30). 441 
CPD=cefpodoxime (10 µg); CA= clavulanic acid (10 µg); CX=cloxacillin (500 µg); 442 
MER = meropenem (10 µg). º = mild outlier; * extreme outlier.   443 
 444 
TABLES 445 
 446 
Table 1. Summary of  ESBL, AmpC, ESBL+AmpC and carbapenemase-producing 447 
isolates used in the present study. Abbreviation for Organism; EC = E. coli, KP = K. 448 
pneumoniae, EA= E. aerogenes, ECL = E. cloacae, MM= M. morganii, CF=C. freundii, 449 
KOX= K. oxytoca, KOZ= K. ozaenae.  Abbreviation for β-lactamase; ESBL=extended-450 
spectrum-β-lactamase, KPC= Klebsiella pneumoniae carbapenemase, MBL = metallo-451 
β-lactamase 452 
Table 2  Interpretation criteria, sensitivity, and specificity of the RCA plate assay with a 453 
combined disc method for rapid screening of ESBL, AmpC, and co-producers of ESBL 454 
and AmpC among Enterobacteriaceae. CPD=cefpodoxime (10 µg); CA= clavulanic 455 
acid (10 µg); CX=cloxacillin (500 µg). 456 
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List of Abbreviations  458 
ATCC American Type Culture Collection  
BA Boronic acid 
CPD Cefpodoxime  
CA Clavulanic acid 
CLSI Clinical Laboratory Standards Institute 
CX Cloxacillin 
ESBL Extended-spectrum-β-lactamase 
KPC Klebsiella pneumoniae carbapenemase 
MBL Metallo-β-lactamase 
MER Meropenem 
NCTC National Collection of Type Cultures 
RCA Resazurin chromogenic agar 
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